About Us

An AI-driven, expert-reviewed CRO, built to scale

Astinova Bio Labs is an AI-driven, expert-reviewed contract research and manufacturing organization — every route AI-designed and verified by PhD synthetic chemists — delivering pioneering chemistry across pharmaceutical intermediates, specialty chemicals, impurities and active pharmaceutical ingredients — founded by synthetic chemists with a vision to provide best-in-class pharmaceutical services.

Our Mission

Enabling the chemistry that changes medicine

We exist to make the most complex and impactful chemistry in drug discovery accessible to biotechs, pharmaceutical companies and academic drug-discovery groups worldwide.

By pairing a curated AI retrosynthesis engine with deep chemistry expertise, we help partners move faster, with better compounds, from idea to clinical candidate. The engine proposes; a PhD synthetic chemist verifies, scales and costs every route. Automation makes us fast; expertise makes us right.

Core business

Custom synthesis

Specialty chemicals and organic materials, mg to kg scale.

Process R&D

Non-infringing route development and scheme optimization.

APIs & intermediates

Active pharmaceutical ingredients and key starting materials.

Contract research

mg to multi-kg deliveries under GMP-standard quality.

Why Astinova

Bench-grade chemistry, AI-grade speed

Dual expertise

Discovery medicinal chemistry and scalable process chemistry under one roof.

Proprietary tooling

A curated AI stack you cannot buy off the shelf — engine, drug corpora and retrieval combined.

Founder-led, chemist-built

Founded and led by a PhD synthetic chemist with postdoctoral process-chemistry experience — every report carries that bench-and-plant judgment.

Verification culture

A discipline of checking every claim — the reason clients trust what we hand them.

Confidential partner

NDA-backed, single-expert handling — built for sensitive early-stage chemistry.

Honest reporting

When a route is weak, we say so and show the real chemistry. Credibility is the product.

In-House Innovation

Our own discovery pipeline

Beyond services, we invest in first-in-class chemistry of our own — an internally funded discovery program advanced in-house.

ProgramABL-2025-07 · NCE #1
ModalityOral PROTAC degrader
IndicationBreast cancer (HR+)
AttributesFirst-in-class, orally bioavailable

CRBN ligand (pomalidomide-type)

Pomalidomide-type CRBN ligand
HIT
2026
LEAD
2027
GLP Tox
2028

Let's talk chemistry.

Whether you have a known target or a novel scaffold, we return scale-matched, costed, verified routes.

Start a Project